This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit.

Radiopharm Doses First Patient in Phase I Prostate Cancer Radiotherapy Study
Alpha‑Emitting PSMA Therapies Gain Momentum Across Radiopharma Leaders
Ratio Therapeutics Highlights the Next Wave of Radiopharmaceutical Manufacturing Standards
Radiopharma Veterans From Novartis‑Built Platforms Strengthen Emerging Biotechs
Radiopharma Takes Center Stage as Global Biopharma Partnering Accelerates

Selecting the Right Radioisotope: Maximizing Therapeutic Effect While Minimizing Risk

Selecting the Right Radioisotope: Maximizing Therapeutic Effect While Minimizing Risk

9:30 am - Tuesday 21st July 2026

Evaluating isotope properties including half-life and emission type
Assessing radiochemical behavior for stability and efficacy
Comparing isotopes for therapeutic versus diagnostic applications

Speakers:

Michael Groaning

Chief Scientific Officer

Soricimed Biopharma Inc.